Annovis Bio
ANVS
31 hedge funds and large institutions have $23.1M invested in Annovis Bio in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.
900% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 2
303% more capital invested
Capital invested by funds: $5.73M → $23.1M (+$17.4M)
138% more funds holding
Funds holding: 13 → 31 (+18)
0.98% more ownership
Funds ownership: 11.03% → 12.01% (+0.98%)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.15M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$955K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$590K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$481K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$7.41M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.92M |
| 3 |
SIAP
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
|
-$405K |
| 4 |
LIG
Lokken Investment Group
Lewes,
Delaware
|
-$317K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$160K |
ANVS Hedge Fund Activity: Q1 2021 in Review
31 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2021, worth a combined $23.1M — up 303% from $5.73M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ANVS positions and 2 closed out — a net gain of 18 holders — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $4.14M. The largest seller was AIGH Capital Management, cutting an estimated $7.41M.
- 31 institutional investors held Annovis Bio (ANVS) as of Q1 2021, up from 13 in Q4 2020.
- Funds reported $23.1M of Annovis Bio stock for Q1 2021, up 303% quarter-over-quarter.
- 20 funds opened new Annovis Bio positions in Q1 2021 and 2 closed out, a net change of +18 holders.
- The largest Annovis Bio buyer in Q1 2021 was Ikarian Capital, an estimated $4.14M added.
- The largest Annovis Bio seller in Q1 2021 was AIGH Capital Management, an estimated $7.41M sold.
Based on aggregated 13F filings for Q1 2021.